A systematic review of the role of human papillomavirus testing within a cervical screening programme.

Cuzick, Jack; Sasieni, Peter; Davies, Philip; Adams, Jo; Normand, Charles; Frater, Alison; M, van Ballegooijen; E, van den Akker

doi:10.3310/hta3140

Cited by 165 publications

(92 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To further enhance the validity of the figures on sensitivity and specificity of both cytology and testing for HPV-DNA a meta-analysis of major population-based trials was conducted (⊡ Table 3 [12,13,14,15,16,17,18]). …”

Section: Eur J Health Econom 3 · 2003 210mentioning

confidence: 99%

Economic evaluation of human papillomavirus screening in Germany

Mittendorf¹,

Petry²,

Iftner

et al. 2003

The European Journal of Health Economics

View full text Add to dashboard Cite

Cytology-based screening programs for cervical cancer have been effective in reducing cancer incidence and preventing premature deaths worldwide. However, there is concern about the relatively low sensitivity of current screening procedures. Although the causal association between infection with certain high-risk types of human papilloma virus (HPV) and the development of cervical cancer has been clearly established, testing for the major risk factor is not part of current screening practice. We created a tree decision model over time to evaluate different policy choices for implementing a population-based screening program. Results of the economic analysis indicate that testing with any implemented HPV DNA testing (stand alone or in combination with the Papanicolaou smear) is superior to cytology and measures presently in use. Additional costs per life-years gained cannot be reported because the HPV branches had fewer discounted overall costs (euro 222 million vs. euro 82 and euro 76 million, respectively), and they saved more life years (19,599 vs. 19,163 and 903, respectively) then the smear alternative. Any HPV DNA testing is preferable over the current state of the art performed in Germany. This is true not only for economic reasons but also for life-years gained. Therefore HPV DNA testing must become an essential component to back up the relatively weak sensitivity of the standard procedure.

show abstract

Section: Eur J Health Econom 3 · 2003 210mentioning

confidence: 99%

Economic evaluation of human papillomavirus screening in Germany

Mittendorf¹,

Petry²,

Iftner

et al. 2003

The European Journal of Health Economics

View full text Add to dashboard Cite

show abstract

“…To date, however, there are no standard practice guidelines on the optimal methods of surveillance of patients. Several years ago, based on data from patients treated for high-grade cervical intraepithelial neoplasia (CIN) [1][2][3], it was hypothesised that human papillomavirus (HPV) testing may have a role in this setting [4,5]. The rationale was that HPV testing, owing to its supposedly high negative predictive value (NPV), can help to determine quickly and accurately whether treatment has http://dx.doi.org/10.1016/j.jcv.2015.07.007 1386-6532/© 2015 Elsevier B.V. All rights reserved.…”

Section: Introductionmentioning

confidence: 99%

The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma

Costa

Sideri

Negri

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

“…The relationship between noncompliance with screening guidelines and estimates of cervical cancer incidence has been established [21][22][23]. First, many studies demonstrated a relationship between the reduced incidence of cervical cancer and the implementation of CS programs [1,[11][12][13][14][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

“…First, many studies demonstrated a relationship between the reduced incidence of cervical cancer and the implementation of CS programs [1,[11][12][13][14][20][21][22][23]. In one of these studies, 35% of the 148 women with invasive cervical cancer had undergone CS only occasionally and 37% had never undergone CS.…”

Section: Introductionmentioning

confidence: 99%